Is UK Venture Capital Facing a New Era of Selectivity?

UK venture capital deal volume dropped by 14 percent and funding value by 11 percent in the first seven months of 2025 compared to the previous year, driven by macroeconomic factors and a shift toward quality investments. The UK remains among the top five global VC markets, accounting for 7 percent of global deals and 4 percent of global deal value. Major 2025 UK deals include $600 million for Isomorphic Labs, $411 million for Verdiva Bio, $350 million for PS Miner, $300 million for Rapyd, $200 million for CMR Surgical, $180 million for Synthesia, and $160 million for Xelix. The technology and healthcare sectors continue to attract significant investment, and analysts indicate the market is moving toward more disciplined capital allocation.

Learn more on this news by visiting us at: https://greyjournal.net/news/

Hosted on Acast. See acast.com/privacy for more information.